Partners

Our partners

We share our vision with our R&D and commercialization partners including local research centers and tertiary hospitals and global pharmaceutical companies.

Local and global
pharmaceutical companies

R&D centers,
Research oriented hospitals

Local and global
pharmaceutical companies

R&D centers,
Research oriented hospitals

A clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer (2019.12)

Clinical partnership of phase 1/1b combination clinical trial with Genome & Company’s GEN-001, microbiome-based immuno-oncology therapy, and avelumab (BAVENCIO®), Merck KGaA, Darmstadt, Germany and Pfizer Inc.’s anti-PD-L1 antibody in oncology indications.

LG Chem. Commercialization License Deal (2020.04)

G&C has entered a world’s first license-out deal of a microbiome immuno-oncology therapeutic in the world with LGC for GEN-001. Under the terms of the deal, LGC will hold exclusive rights for clinical trials and commercial distribution in Korea and other Asian countries. In return, G&C will be received the upfront payment with the potential of receiving a further payment of milestones and royalties, and its deal value is undisclosed.

Joined with the double antibody developing company, ABL Bio Inc., for the development of the new ‘Immune Checkpoint Inhibitor’ (2019.01)

G&C has entered a R&D collaboration agreement for ‘Immune Checkpoint Inhibitor’ with ABL Bio, a biotech research company focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases. The new ICI is targeted non-responders of anti-PD1, where G&C will be developing pre-clinical stage for target identification and validation and ABL Bio will be responsible for anti-body development and manufacturing process.

G&C and Samsung Medical Center sign new MOU for developing immuno-oncology drugs

The MOU will bring a collaboration of ‘bench-to-bedside’ technical platforms from G&C and ‘bedside to bench’ platform from Samsung Seoul Hospital that will be bring the synergy for next immuno-oncology drugs.